Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Wienbergen
Harm
H
Institut für Herzinfarktforschung an der Universität Heidelberg, c/o Klinikum Ludwigshafen, Bremserstrasse 79, 67063 Ludwigshafen, Germany.
Senges
Jochen
J
Gitt
Anselm K
AK
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D048909:Diabetes Complications / Q000453:epidemiology / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D040242:Risk Reduction Behavior
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin